# US 2021/0260000 A1 · The use of actarit in the prophylaxis or treatment of renal fibrosis or kidney disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260000 A1
- Document ID: US20210260000A1
- Status: Published application
- Kind: A1
- Application number: 17/255,364
- Filed: 2019-06-25
- Published: 2021-08-26
- Earliest claimed: 2018-06-27
- Assignees: Algernon Pharmaceuticals Inc.
- Applicants: Algernon Pharmaceuticals Inc.
- Inventors: Mark WILLIAMS
- Web page: https://patentgrep.com/patent/US20210260000A1

## CPC

- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/136: having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/4164: 1,3-Diazoles
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/4741: condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Iguratimod, Repirinast, Lobenzarit, Actarit, Ifenprodil, Bemithyl, Bromantane, Emoxypine, Udenafil, and/or Istradefylline are used for the treatment or prophylaxis of renal fibrosis, kidney disease, or chronic kidney disease in a subject.

## Claims

### Claim at position 1

1-116. (canceled)

### Claim 117

A method for the treatment or prophylaxis of renal fibrosis or kidney disease in a subject, the method comprising:
administering a therapeutically effective amount of Suplatast Tosylate to the subject.

### Claim 118 (depends on 117)

The method of claim 117, wherein the amount of Suplatast Tosylate is between 1 to 20 mg per kg of the subject.

### Claim 119 (depends on 118)

The method of claim 118, wherein the amount of Suplatast Tosylate is between 2 to 10 mg per kg of the subject.

### Claim 120 (depends on 119)

The method of claim 119, wherein the amount of Suplatast Tosylate is about 5 mg per kg of the subject.

### Claim 121

A method for the treatment or prophylaxis of renal fibrosis or kidney disease in a subject, the method comprising:
administering a therapeutically effective amount of Bromantane to the subject.

### Claim 122 (depends on 121)

The method of claim 121, wherein the amount of Bromantane is between 0.5 to 10 mg per kg of the subject.

### Claim 123 (depends on 122)

The method of claim 122, wherein the amount of Bromantane is between 1 to 3 mg per kg of the subject.

### Claim 124 (depends on 123)

The method of claim 123, wherein the amount of Bromantane is about 1.7 mg per kg of the subject.

### Claim 125 (depends on 121)

The method of claim 121, wherein the amount of Bromantane is between 1.7 to 3.3 mg per kg of the subject.

### Claim 126 (depends on 117)

The method of claim 117, in combination with administering a therapeutically effective amount of one or more of Cenicriviroc, Telmisartan, a cholesterol lowering drug, an antihypertension drug, or erythropoietin.
